Michael Alvarado, M.D. is a Professor of Surgery and member of the breast care and melanoma programs. Just recently, he was appointed Accountable Care Medical Director. Dr. Alvarado received his undergraduate degree from Arizona State University, his master’s degree in chemistry from the University of Arizona and his medical degree from Dartmouth Medical School.
After completing his residency at Dartmouth-Hitchcock Medical Center, he completed his surgical oncology fellowship at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida.
Dr. Alvarado plays an integral role in the multidisciplinary breast care team at the Carol Franc Buck Breast Care Center in the UCSF Helen Diller Family Comprehensive Cancer Center. He is also Director of the Breast Surgical Oncology Fellowship Program.
William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer and cancer genomics, with over 30 years of experience as a clinician and clinical researcher at the Cedars‐Sinai Cancer Center in Los Angeles. Dr. Audeh completed his Internal Medicine training and Medical Oncology Fellowship at the Stanford University Medical Center in California, and holds a master’s degree in Genetics from the University of Minnesota.
He is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, and the American Society of Human Genetics.
Professor John Benson is a Consultant Breast Surgeon at Addenbrooke’s Hospital, Cambridge, Affiliated Assistant Professor, University of Cambridge and Visiting Professor, School of Medicine, Anglia Ruskin University. He has previously been actively involved with the San Antonio Breast Cancer Symposium as a member of the Planning Committee and Career Development Forum (2011–2015). He has published more than 160 papers (including 30 in the Lancet/Lancet Oncology) and written/edited 8 books. He is currently ranked in the top 0.076% of breast cancer experts worldwide (Expertscape). He was elected Honorary Secretary of the Association of Breast Surgery in 2023.
John Benson 1st March 2024
James Blackwood is an independent healthcare augmented intelligence (AI) expert who has delivered over 65 AI projects, from initial research concept to clinical adoption at scale, in areas such as population health, primary care, mental health, radiology (including breast cancer screening), pathology (including breast cancer histology) and hospital operations management.
He is currently the AI Lead for NHS Forth Valley, Chief Technology Officer for several healthcare startups, consultant, speaker and a course co-lead for AI in healthcare at the University of Edinburgh. He is Scotland’s Digital Health and Care Leader 2024.
Paula Briggs is a Consultant in Sexual and Reproductive Health based at Liverpool Women’s NHS Foundation Trust.
She is Immediate Past Chair of the British Menopause Society.
Paula qualified from University of Glasgow in 1987.
She trained as a GP before moving to Liverpool in 1993 and worked in General Practice and Sexual Health until 2012.
She is now devoted to delivery of women’s health care, research and education. She is an Honorary Senior Lecturer at the University of Liverpool. Her main interest is menopause management with a particular interest in urogenital atrophy.
She has co-edited 3 books, (one second edition), co-written an undergraduate textbook in Obstetrics and Gynaecology, a revision guide for MFSRH and a book specifically for men about female hormones. She has also written a patient booklet on menopause (second edition). She co-authored a myth busting book on contraception for the lay public and is working on a similar menopause patient book with colleagues currently. She also has 2 new patient booklets, one co-authored on sexual and reproductive health after gynaecological cancer and the other on urogenital atrophy.
She is married with four children and enjoys golf, reading and cooking.
Mr Henry J Cain MBChB (hons) FRCS, MD
Henry Cain qualified in 2001 from Leicester Medical School. Following the award of MD in breast cancer signalling pathways and higher surgical training in Newcastle upon Tyne he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow. He was appointed a Consultant Oncoplastic Surgeon at the Royal Victoria Infirmary Newcastle upon Tyne in 2013. Driving improvements in surgical care he has led the introduction of Radioactive Seed Localisation of impalpable breast cancer and post neo-adjuvant chemotherapy I125 seed Targeted Axillary Dissection to the UK. With a significant recruitment into national trials he is the surgical lead Co-Investigator for the NOSTRA trial and the Chief Investigator for the PRE-DX national RCT.
Dr. Julia Camps Herrero is a breast radiologist and also the Corporate Head of Breast Health in Ribera Salud Hospitals (Spain). Since 1999 she is an active researcher in multimodality breast radiology, with a special interest in contrast imaging (MRI and CEM). Dr. Camps Herrero is an active speaker in Latin America and Europe, where she has been invited in more than 400 presentations. She is the author of 23 papers, 7 book chapters and 75 scientific posters and oral presentations. She has been the Breast section editor for EURORAD 2007-2017, chairman of the ECR 2012 Breast Subcommittee and of the Spanish Senology Congress in 2015, member of the Programme Planning Committee for ECR 2015, 2016 and 2022. Presently, she is the Vice-president of SEDIM (Spanish Breast Imaging Society) and an ex-President of the European Society of Breast Imaging (EUSOBI).
Miss Leena Chagla is the President of the Association of Breast Surgery and the past President of the Liverpool and Northwest Society of Surgeons. She heads the breast unit at Mersey and West Lancashire Teaching Hospitals which is actively involved in clinical innovation and trials. She continues to publish regularly in peer reviewed journals.
Leena qualified from Grant Medical College, Mumbai, with a gold medal in Surgery. Whilst in India, she trained at the Sir JJ Hospital and at the Tata Memorial Cancer Centre. Her passion for surgical oncology developed in those formative years.
She is a popular speaker both nationally and internationally and is involved in the development of guidelines for the management of breast cancer. She is passionate about MDT working and the welfare of trainees. She launched the Anti-bullying Campaign (#CoreItOut) for ABS in alliance with RCSEd. She represented ABS on the pathology Big 18 and the organising committee of Symposia Mammographicum.
Leena was instrumental in setting up the International Forum at ABS with a view to sharing good practice globally. She is committed to improving and standardising Breast cancer care through education and training. She is an Educational Supervisor for the National Oncoplastic Fellow for the last 20 years and she has trained international trainees from LMICs on the MTI scheme since 2018. She represented Liverpool and Northern Counties in water-polo, and she enjoys all sport.
Krishna Clough
Dr CLOUGH is a leader in Oncoplastic Breast Surgery, having been instrumental in its creation and subsequently developing the classification of oncoplastic surgery techniques which is considered a reference paper in this field. He spent more than 15 years in the French public system, and was the Chief of Surgery at the Institut Curie in 1996 at the age of 38. In 2004, Dr CLOUGH left the Institut Curie to create the Paris Breast Centre, France’s first Breast Centre, which now hosts 6 breast surgeons and a multidisciplinary team of 20 physicians dedicated to the care of women with breast cancer, but also benign breast disease, and cosmetic breast surgery. The Paris Breast Centre is one of the leading institutions in France for treatment and education with widely reputable international fellowships for young surgeons early on in their career and experienced surgeons from all over the world wishing to undertake oncoplastic training.
Dr CLOUGH is a dually qualified surgical oncologist and a plastic surgeon, having specialised early in breast surgery. He has focused on offering patients the benefits of a multidisciplinary approach whilst limiting the side effects of each of the treatments applied. His clinical research aims at developing a global surgical expertise for breast surgery, from non-palpable breast cancer to all types of breast reconstruction, including all possible surgical procedures for diagnosis, treatment and reconstructive surgery of the breast. In the late 1980’s Dr CLOUGH developed the concept of oncoplastic surgery for breast conservation, integrating plastic surgery techniques at the time of the tumour resection, in order to extend breast conservation possibilities and reduce postoperative sequelae. He published the first papers on oncoplastic surgery techniques and results in the early 1990’s, demonstrating that oncoplastic procedures could extend the scope of breast surgery, which was initially limited to wide local excision or mastectomy. Fully integrated into a multidisciplinary treatment, the concept of oncoplastic surgery is now spreading worldwide in the field of breast oncology, and is considered as one of the main recent advances in breast cancer surgery.
Dr CLOUGH has published over 160 articles in international peer reviewed journals and continues his clinical research in the busiest private practice in France. He has been invited to present in all major international conferences and represented France in numerous international working groups (consensus conferences), whose works have been the object of reference publications. Dr CLOUGH was awarded the Umberto Veronesi European Institute of Oncology award in 2015, for his contribution to breast cancer treatment and education. He is currently the Vice President of the French Society of Senology.
Dr John Conibear graduated from the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006.
Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded a MD(Res) from UCL in 2018.
Dr Conibear is currently the clinical director for thoracic and neuro-oncology in St. Bartholomew’s Hospital and, the oncology clinical lead for the National Lung Cancer Audit (NLCA).
Dr Conibear specialises in all the non-surgical treatments for both breast and lung cancers and has a specialist interest in stereotactic radiotherapy. He is trained in using the ViewRay MRIdian MRI-guided linac, Accuray Cyberknife and Leksell Icon Gamma Knife platforms for delivering both intra- and extra-cranial stereotactic radiotherapy.
Javier Cortés, MD PhD
• International Breast Cancer Center (IBCC), Barcelona, Spain
• Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
• Medica Scentia Innovation Research (MedSIR), Barcelona, Spain & New Jersey, US
Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996, specialist in Medical Oncology by the Clínica Universitaria de Navarra, and awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology. In addition he was the Head of the Breast Cancer Program from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr. Cortes was the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, from 2011 to September 2020. He has been Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology from 2011 to February 2022.
Dr. Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials.
In addition to his medical specialties, he has two master degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
He has contributed to over 430 peer-reviewed publications, especially about breast tumours and new drugs and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society for Medical Oncology (ESMO), of the Scientific Committee of the European Breast Cancer Conference (EBCC), has been chair for breast cancer at the ESMO 2020 congress, and co-chair of the same section in the congress of the American Association for Cancer Research (AACR) 2020, as well as the immunotherapy area of the AACR 2021 congress. He is a member of the expert panel that develops the treatment guidelines for metastatic breast cancer of the European Society for Medical Oncology, member of the ABC Conference, member of the ASCO International Affairs Committee, member of the executive panel in charge of SABCS Strategic Planning, and co-organizer of the Annual Congress of Controversies in Breast Cancer (CoBrCa).
In addition, according to the American Expertscape 2023 ranking, he is considered the world’s leading expert on HER2+ and fourth world oncologist with the greatest expertise in breast cancer and in 2022 and 2023 was identified as Clarivate™ world’s most influential researchers.
Ramsey Cutress is Professor of Breast Surgery in Southampton, topic advisor for the NICE Breast Cancer Guidelines and co-director of the Association of Breast Surgery (ABS) Advanced Skills in Breast Disease Management Course. Clinical research interests include breast cancer in young women as a member of the POSH study research team, and investigation of patient and host determinants of breast cancer outcomes including genetic predisposition, immunological and lifestyle factors. He is lead investigator for the HTA funded EndoNET neo-adjuvant endocrine therapy trial, and breast sub-specialty editor for the Annals of the Royal College of Surgeons of England.
Mr Rajiv Dave is Consultant Oncoplastic Breast and endocrine surgeon with a strong academic and leadership portfolio, based at Manchester University NHS Foundation trust. He has previously held a research fellowship (Leeds; awarded the Patey Prize by the Society of Academic and Research Surgery), an international clinical fellowship (Melbourne; Breast, Endocrine and Melanoma), and a National TIG Oncoplastic Fellowship, and has previously served as the Associate Surgical Speciality Lead (aSSL) for Breast Surgery at the Royal College of Surgeons. He is a member of the Association of Breast Surgery Academic and Research Committee and the International Committee. He has successfully delivered large national and international collaborative studies which have informed and impacted clinical practice, and has been awarded prestigious research grants. He is a founder steering member of the Kenya UK Health Alliance, and has led and delivered practical and effective solutions towards addressing the global health challenge of breast cancer.
Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.
Professor Mike Dixon is a Consultant Breast Surgeon at the Edinburgh Breast Unit, and Clinical Director of the Breast Cancer Now Research Group in Edinburgh and holds an Honorary Professorship in Breast Surgery at the University of Edinburgh. In 2013 he received an OBE from HRH The Queen for his work improving our understanding and management of breast disease. He has published over 330 papers, contributed 130 book chapters, and written or edited 25 books. He has given over 200 invited lectures, was the Royal College of Surgeons of Australasia Visiting Fellow in 2000 and 2011, and was visiting Professor to Yale and Harvard in 2012.
Professor Michael Douek, Professor of Surgical Sciences & Breast Cancer at the University of Oxford, is President of the British Association of Surgical Oncology (BASO). He is an oncoplastic breast surgeon and his research focuses on clinical trials in breast cancer including EndoNET and RESTORE B. He also evaluates other novel techniques for cancer surgery, including a novel magnetic technique for sentinel node biopsy and lesion localization, which he developed. In 2015, he was awarded a Hunterian Professorship by the Royal College of Surgeons of England and in 2019 he was appointed Research Professor at the Royal College of Surgeons of England.
Sarah Downey undertook Surgical training in Yorkshire and moved to East Anglia in 2005. Worked in both Breast and General Surgery for 20 years. MRCS examiner and Chair of the Court of examiners in early years. Undertook Divisional Director role in own hospital for 5 years – opened new daycase unit. Acted as Regional Breast Screening QA Surgeon for 6 years. Joined General Surgery SAC ( National Training Committee) in 2015 and chaired the committee until Jan 2024, implementing new curriculum. Became regional Training Programme Director, looking after 90 Higher Surgical trainees, in 2018 to present. Currently undergraduate PBL tutor; online tutor for oncoplastic MS, Honorary Associate Professor UEA, Clinical Appraisal Lead and National Online Training Programme Director for General Surgery. Former Oncoplastic training fellowship (TIG) Chair and faculty on Advanced Breast Cancer Course. Currently Vice President of ABS.
Kenneth Elder is currently a consultant breast surgeon at the Western general hospital in Edinburgh where he is the breast lead for the University of Edinburgh ChM qualification.
He undertook his undergraduate medical training at the University of Nottingham qualifying in 2008. At the end of his medical career he travelled to East Timor to work as a disaster relief doctor and was awarded The Worshipful Society of Apothecaries of London prize for Conflict and Catastrophe Medicine. He completed his higher surgical training in Edinburgh and surrounding hospitals. During his training he completed a research fellowship at the Peter Macallum Cancer Research Centre in Melbourne Australia under Professor Bruce Mann and Professor Iain Campbell looking at the efficacy of modern breast screening and the genetics of pre-cancerous breast disease. For his time there he was awarded the Ethicon travelling scholarship. This research has been published widely and has been presented around the world. He returned to Australia to complete a clinical fellowship under Professor Bruce Mann at the Royal Women’s Hospital of Melbourne. Mr. Elder is also an invited member of the teaching faculty at the Royal College of Surgeons of Hong Kong.
Katy Ellis specialised in surgical nursing and began her career in the operating theatres in 1996, later becoming a Surgical Care Practitioner. Her passion for caring for breast patients led her to work as a Lead Clinical Nurse Specialist, an Advanced Clinical Practitioner and now a Nurse Consultant in breast care at Manchester University Foundation Trust.
Katy has worked in a small symptomatic as well as a large screening and symptomatic unit. Katy is passionate about nursing and quality patient care and is the new Nurse Trustee for ABS and strives to influence change and innovation.
Matthew Ellis
I am a Physician Scientist dedicated to improving outcomes for patients with cancer with a focus on next gen diagnostics, target discovery and translational medicine. I was Co-leader for The Cancer Genome Atlas (TCGA) Breast Project where I established collaborations with several Genome Centers on massive parallel sequencing of breast cancer (Nature, 2010, 2012, 2012). With support from the NCI program “Specialized Program for the Evaluation of Cancer Signatures (SPECS)”, I co-developed the PAM50-based diagnostic platform which is now available as the Nanostring-based device “Prosigna” – approved in over 20 counties for the determination of prognosis in ER+ HER2- early-stage breast cancer (JCO 2009). Deepening my diagnostics/discovery experience, I was a principal investigator in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) for over a decade. CPTAC is focused on translating proteogenomic findings into improvements in the diagnosis and treatment of common solid malignancies (Nature 2016, Nature Communications 2020, Cell 2020, Cancer Discovery 2022, Clinical Proteomics 2023). Motivated by a desire to have a greater impact and to expand my clinical impact beyond breast cancer I took the position of Senior Vice President Early Oncology at AZ in early 2022. I led a large organization focused on cancer drug development; from target identification through to Phase 2 clinical trials. In April 2024 I left AZ to start the Philanthropy-driven Institute for Proteogenomic Discovery. The vision for the institute is the generation large-scale publicly accessible digital cancer maps for biomarker and therapeutic target discovery based on proteogenomic technologies and artificial intelligence.
Prof D. Gareth Evans , MB, BS, MD, FRCP, FLSW, FRCOG, ad eundem
A Consultant at Manchester University Hospitals NHS Foundation Trust and The Christie NHS Foundation Trust, Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis, schwannomatosis and breast cancer. Professor Evans is a chair of medical genetics and cancer epidemiology at the University of Manchester. He has published 1060 peer reviewed research publications, 355 as first or senior author as well as over 150 reviews, letters and chapters. In the last eight years he has raised over £75 million in grants for multicentre and local studies. He is Chief Investigator on two NIHR program grants on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is the cancer prevention early detection theme leader on the NIHR Manchester Biomedical Research Centre. Professor Evans is also lead clinician on the NICE Familial Breast Cancer Guideline Group.
Professor Evans is recognised as the international leader in the genetics and epidemiology of Neurofibromatosis type 2 and his ground-breaking research on mosaicism and mortality has had a major impact on treatment of this serious inherited condition. The National Highly Specialised Service for NF2 he leads pioneered use of the drug bevacizumab which along with multidisciplinary care has already improved survival and quality of life for this life-limiting condition. In 2013 he led the team that identified SMARCE1 as the cause of the related condition hereditary clear cell meningioma. Work in Gorlin syndrome led to the discovery of SUFU as a cause of Gorlin syndrome that has redefined the risks of the associated childhood brain cancer, medulloblastoma (SUFU~30%; PTCH1~2%). He is an emeritus two term NIHR Senior Investigator and has published widely (H-index-118 Web of Science; 161-Google) and is Cancer Prevention theme lead on the all-Manchester BRC and is frequently invited as a keynote speaker to scientific conferences at home/abroad. He is now co-lead on the Manchester CR-UK ICED Alliance Early detection initiative. He was a moving force of the Prevent Breast Cancer Appeal which helped establish the first dedicated breast cancer prevention centre in Europe (https://preventbreastcancer.org.uk/about-us/the-nightingale-centre/) and has been a trustee of five charities including Breast Cancer Now (previously chairman of the Scientific Advisory Board) and the Neuro Foundation.
Professor Dame Lesley Fallowfield is Director of Sussex Health Outcomes Research & Education in Cancer (SHORE-C) psycho-oncology group at Brighton & Sussex Medical School. Her wide research interests include quality-of-life measurement in cancer therapy trials, development of patient information materials and evidence-based communication programmes for healthcare professionals. She has won numerous prestigious research awards, is a Fellow of the Academy of Medical Sciences and was made Dame Commander of the Order of the British Empire in 2016.
Mr Douglas Ferguson attended St George’s University of London, in 1990 was awarded BSc (Hons) and completed MBBS, with merits, in 1993. He was awarded FRCS (England) in 1997 and Master of Surgery in 2005. Also in 2005 Douglas was the UK and Ireland Gold medal winner for Intercollegiate FRCS on completion of his training. He was appointed as the Royal Devon & Exeter’s first Oncoplastic Breast Surgeon in April 2006. He completed a PGCert in medical education 2018.
His current roles at the RDE and nationally include; Clinical Lead Breast Services (Surgery and Radiology); the PI for multiple International Trials, – ARB, LORIS, PALLET, MAMMO50, POSNOC, POETIC, IBISII, FH01 FH02, ATNEC, POETIC A, SMALL, IMPARTER and CANDO3. He is a Breast Tutor for Royal College of Surgeons of England, faculty for the National Oncoplastic Fellowships and Master of Oncoplastic Surgery Degree and an Honorary Associate Professor for the University of Exeter Medical School. He is also the Association of Breast Surgery rep for the National Breast Trainee Interface Group for the Oncoplastic Breast Fellowship. Douglas is the Chairman South West for the Oncoplastic Breast Surgeons (SWOBS) group and convenor of its course. He is a University Representative for RD&E and Royal College Representative for Consultant Appointment Committees and is also a Peninsular Doctors Mentor. He is the current Honorary Treasurer Association of Breast Surgery.
Mr Ferguson is also Chairman of West Hill Wasps Junior Football; coaches under 14’s team and is the club’s Welfare officer. In his spare time he plays local league football and continues to learn the guitar!
Adam Gilmour is a Consultant Plastic Surgeon / Oncoplastic Breast Surgeon at the Canniesburn Plastic Surgery Unit in Glasgow.
At the end of training he completed one of the Nationally appointed Trainee Interface Group (TIG) fellowships in Oncoplastic Breast Surgery. He subsequently served as the BAPRAS representative on the Oncoplastic TIG committee for two years.
He offers all aspects of breast reconstruction but also performs oncology procedures. He is a member of the breast cancer MDT for NHS Ayrshire & Aaron and believes in collaborative working and ensuring exceptional patient care.
Amit Goyal is a Consultant Oncoplastic Breast Surgeon, Associate Professor, and Clinical Lead of Breast Surgery at University Hospitals of Derby & Burton NHS Foundation Trust. His research focuses on axillary management in breast cancer and breast reconstruction. As Chief Investigator, he leads major UK breast cancer surgical trials, including POSNOC and ATNEC, investigating axillary treatment. Additionally, he leads the BIOSYM trial, comparing synthetic and biological matrices in breast reconstruction.
Dr. Stephen R. Grobmyer, MD, is the Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Grobmyer was Professor of Surgery, Section Head of Breast Surgery and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program at Cleveland Clinic Main Campus in Cleveland, Ohio, USA.
Dr. Grobmyer received his medical degree from the University of Texas Southwestern Medical School in Dallas, Texas and completed his residency in General Surgery at New York Hospital-Cornell Medical Center in New York. He completed a fellowship in Surgical Oncology at Memorial Sloan Kettering in 2004.
Dr. Grobmyer’s innovative clinical care and research focuses on developing new approaches to prevent, diagnose and treat breast cancer. He has published over 200 peer-reviewed manuscripts and 20 book chapters. Additionally, he has given over one hundred invited lectures nationally and internationally.
Dr. Grobmyer has been the recipient of numerous prestigious awards including, The Lester Dragstedt Physician Scientist Award, The Society of Surgical Oncology Clinical Investigator Award and The American College of Surgeons Japan Travelling Fellowship. He is a member of the American Surgical Association. His influential clinical care and research has been featured widely in the Unites States media including NBC Nightly News, MSNBC, National Public Radio, The New York Times and Vogue.
Dr Stephen Harrow is a consultant Clinical Oncologist. He completed a PhD combining radiation and viro-therapy in high grade glioma prior to completing his specialist clinical oncology training. Dr Harrow then undertook a fellowship in Radiation Oncology with the British Columbia Cancer Agency in Vancouver. There, he was involved in several research projects including initiating their Stereotactic Body Radiotherapy lung programme. He returned to the Beatson West of Scotland Cancer Centre in 2009 to take up a consultant position and then moved to the Edinburgh Cancer Centre in 2021.
At the Edinburgh Cancer Centre Dr Harrow delivers both radiotherapy and systemic anti-cancer therapy for thoracic malignancies and oligometastatic disease. He was awarded a National Research Scotland Fellowship from the Chief Scientists office which has allowed him dedicated research time to develop clinical and laboratory research projects. He is the lead clinician for Cancer Innovation and the Scottish Cancer Research Network (South East). He was the UK Chief Investigator for the pivotal SABR-COMET oligometastatic study and is UK lead for the subsequent oligometastatic studies, COMET-10 and COMET-3. He was awarded a 1.8 million pound grant from the Scottish Government to develop oligometastic SABR services across Scotland to ensure equity of access for Scottish patients and clinical trial development. His other research interests are in retreatment with radiotherapy, radiation induced pneumonitis, radiomics and drug/radiotherapy combinations (Concorde arm lead).
Tracey Irvine has been a Consultant Oncoplastic Surgeon in Guildford since 2009. She has a special interest in oncoplastic breast conservation, neoadjuvant chemotherapy and management of the axilla and runs the Guildford gene carrier clinic for patients in the KSS region. In 2015 she was awarded the Murray Brennan Scholarship by the American College of Surgeons and spent two months in the major cancer centres in the US. She is the Clinical Lead for the breast Getting it Right First Time (GIRFT) programme and is CQC Specialty Advisor for breast, developing the new breast specialty specific inspection. In 2022 she was appointed National Clinical Lead for Breast Cancer by NHSE.
Kevin Kalinsky, M.D., M.S. is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Kalinsky serves as the director of the Glenn Family Breast Center at Winship, as well as the Director of the Division of Medical Oncology at Emory.
Professor Cliona Kirwan
Biography:
Consultant Oncoplastic Breast Surgeon, Nightingale Breast Centre, Manchester University Hospital Foundation Trust
Clinician Scientist in Surgical Oncology, University of Manchester
Royal College of Surgeons of England Professor of Surgical Trials
Cliona is an Oncoplastic Breast Surgeon at the Nightingale Breast Cancer Centre in Manchester, UK. She studied medicine, including a BSc in the History of Medicine, at Charing Cross and Westminster Medical School, London and University College London. Her surgical training was in London, Bristol, Bournemouth, South Africa and Greater Manchester. She completed a PhD entitled ‘The Role of Procoagulants in Cancer and Chemotherapy Induced Venous Thromboembolism’ at the University of Manchester in 2006.
She delivers and teaches in all forms of oncoplastic breast surgery including reconstruction. At the University of Manchester, she leads the Cancer and Thrombosis Research Group, performing basic, translational and clinical research, investigating the symbiotic relationship between cancer and thrombosis. She also supervises MRes, MD and PhD students.
She is Chief Investigator on the TIP Trial and CHAMPion Study and surgical lead for LORIS, PRIMETIME, POETIC-A and FAST-Forward Boost and is on the Sloane Committee. Cliona is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, leads the ABS guideline development group for Idiopathic Granulomatous Mastitis and is a key member of the International Society of Haemostasis and Thrombosis guideline development group for VTE in breast cancer. She is Director of the North West Surgical Trials Centre, and mentors the North West Research Collaborative and North West Breast Research Collaborative. She also chairs the Scientific Committee for the Prevent Breast Cancer charity.
Dr Gerald Lip is the Clinical Director for breast screening in the North East of Scotland and the Principal Investigator of the GEMINI prospective evaluation of mammography artificial intelligence supported by the NHS National Strategy for AI in Health and Social Care.
He is a Chief Scientist Office Innovation Fellow, the incoming president of the British Society of Breast Radiology and chairs the British Institute of Radiology AI special interest group.
Dr Lip is active in research, education and training publishing on work with radiology trainees in AI, opinions on the member of the public and professional colleagues on AI.
Iain Macpherson is Professor of Breast Oncology at the University of Glasgow and Honorary Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, where he specialises in the treatment of breast cancer. He is Chief Investigator of the UK HER2-RADiCAL study and co-Chief Investigator of the multi-national OPTIMA trial with both studies aiming to advance more personalised approaches to the treatment of early breast cancer. He also leads a pre-clinical research programme investigating metabolic drivers of breast cancer progression. He is currently Treasurer of the UK Breast Cancer Group and Chair of the Scottish Cancer Trials Breast Group, and has served as a member of the NCRI Breast Clinical Studies Group, the Breast Cancer Now Scientific Advisory Board and the West of Scotland Research Ethics Committee. He trained in medicine at the University of Glasgow, graduating in 1998. He then completed a PhD at the CRUK Beatson Institute and undertook speciality training in Medical Oncology at the Beatson West of Scotland Cancer Centre.
Mr Andy Malyon FRCS(Plast)
Consultant Plastic Surgeon
Professional Advisor to Medical Devices & Legislation Unit Scottish Government
National Clinical Lead, Scan for Safety
Synopsis and Biography:
After 20 years as a consultant plastic surgeon with an interest in breast reconstruction and oncoplastic surgery at the Canniesburn Unit in Glasgow, he has now reduced his clinical sessions to one day of oncoplastic work at Gartnavel General Hospital. The remainder of his time is split between working for the Medical Devices & Legislation Unit in Scottish Government, and the Scottish Scan for Safety Programme delivered by National Service Scotland.
Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.
James Mansell is a Consultant Breast Surgeon with an interest in Oncoplastic Breast Surgery working in Glasgow. Previous Clinical lead of Breast cancer for the West of Scotland Cancer Network. Involved in curating national meetings and Principal Investigator for a number of Clinical Trials.
Yazan Masannat is a Consultant Oncoplastic Breast Surgeon at Aberdeen Royal Infirmary and one of the Associate Post Graduate Deans at NHS Education for Scotland. He is an Honorary Senior Clinical Lecturer at the University of Aberdeen and an E-Tutor with the University of East Anglia. He is on the Board of Trustees of the Association of Breast Surgery, a member of their education and training committee and the meetings secretary. He is also on the Education and training committee for the European Society of Surgical Oncology. He is the communications lead at the iBRA-net in addition to being an examiner at the European Board of Surgical Oncology and the European Board of Breast Surgery exams (UEMS)
Yazan has more than 60 publications and has been awarded numerous research grants including the prestigious NRS Fellowship award by the Chief Scientist Office (CSO) in Scotland. This is to continue research on Novel MRI techniques in Breast Surgery with the Team at the University of Aberdeen which he does on top of his clinical work.
Yazan is also the creator of www.iBreastBook.com which is a free online resource with contributions from many of the leading Breast and Plastic surgeons across the world. The iBreastBook Webinar series, which he started during the covid pandemic with the support of colleagues has been a huge international success.
Stuart McIntosh is Professor of Surgical Oncology at Queen’s University in Belfast, and a consultant oncoplastic breast surgeon at Belfast City Hospital.
Stuart is an experienced clinical trialist, with a particular interest in neoadjuvant, peri-surgical and treatment de-escalation studies, and is Chief Investigator for the UK SMALL trial, as well as holding surgical leadership roles in several other trials. He is also one of the Royal College of Surgeons Surgical Specialty Leads for Breast Surgery, responsible for supporting the development and delivery of breast cancer surgical trials nationally. Additionally, he chairs the Northern Ireland Cancer Trials Network, responsible for the delivery of cancer trials across the five cancer hospitals in Northern Ireland. Stuart’s laboratory research interests include the DNA damage driven immune response in breast cancer.
Dr Jennie Murray is a consultant in Clinical Genetics in Edinburgh and an Honorary Clinical Senior Lecturer at the University of Edinburgh. She is the Cancer Genetics Clinical Lead for Southeast Scotland and the current chair of the Scottish Hereditary Cancer Genetics Group whose aim is to optimise the identification of individuals with an inherited predisposition to cancer and improve prevention and early detection of cancers in this group.
Dr. Olga Oikonomidou is an Academic Consultant Medical Oncologist specializing in breast cancer and Breast Cancer Translational Research Group Leader at the Institute of Genetics and Cancer, University of Edinburgh. Other than a degree in Medicine, she holds a BSc in Human Genetics, MSc in Oncology, MRes in Immunology and a PhD in translational medicine. Her responsibilities are split between running a busy breast oncology practice and leading on a large portfolio of clinical trials and breast cancer translational studies. Dr Oikonomidou is a clinical expert for NICE and SMC and has been involved in numerous technology appraisals since 2015. She has received several prestigious grants for her clinical research projects. She is on the TMG of numerous national and international trials. She is currently the global Chief Investigator of 2 multinational multicentre clinical trials, UK Chief Investigator of 4 clinical trials and the PI for more than 50 trials. Her academic research interest is focused on prediction of biomarkers of response to treatment and clinical trials in breast cancer in all phases.
Professor Carlo Palmieri BSc(Hons), MB BS, PhD, FRCP(UK)
Carlo is a Professor of Translational Oncology at the University of Liverpool and Consultant medical oncologist at The Clatterbridge Cancer Centre NHS Foundation Trust. Carlo’s academic and clinical interest is in breast cancer, and his research interests are focused on hormone therapy for breast cancer and brain metastasis. He is actively involved in developing and initiating translational and clinical research trials and leads a number of studies including a national effort to collect CSF from patients with CNS disease secondary to breast cancer and a study investigating the feasibility of randomising patients with HER2 positive metastatic breast cancer to screening or nor. He co-leads CCP-UK CANCER a national NIHR URI funded project which is characterising COVID-19 in cancer patients. Regionally he co-chairs the Cheshire and Merseyside Cancer Alliance breast group. Nationalize co-chairs the National Cancer Research Institute (NCRI) Breast Working Group 2 (metastatic breast cancer), is a member of the NHS England Genomics Clinical Reference Group and has sat on the Independent Advisory Group which defined the patient groups deemed to be at very highest risk of an adverse COVID-19 outcome, to support the deployment of approved medication for treatment or prophlyaxis. He is a member of the Breast International Group (BIG) brain metastasis task force. He has co-edited ‘ABC of Cancer Care’ which aimed at non-specialists and students.
Dr Marina Parton
Consultant Medical Oncologist BSc MBBS MRCP MD
Dr Marina Parton is a Medical Oncologist in Breast Cancer at The Royal Marsden and Kingston Hospitals. Appointed to The Royal Marsden Consultant Body in 2009, she received her oncology training at The Royal Marsden and conducted her research in neoadjuvant therapy in breast cancer as part of a MD at The Institute of Cancer Research with Professors Dowsett and Smith.
Dr Parton is Lead Cancer Clinician in The Royal Marsden’s only satellite chemotherapy unit, a joint venture with Kingston Hospital and Macmillan Cancer Support. She has published in breast cancer research and is principal investigator in a number of clinical trials at The Royal Marsden and Kingston Hospital. She has previously been Chair of the Acute Oncology Group at The Royal Marsden, part of the Breast Pathway Group at London Cancer Alliance (LCA) and co-chair of the LCA Chemotherapy Closer to Home Group. She participates in a number of national educational groups and meetings in early and secondary breast cancer, and co-edited Breast Cancer Survivorship; consequences of early breast cancer treatment. Dr Parton was member of the NICE Early Breast Guidelines update (published 2018).
Dr. Partridge is a practicing medical oncologist and clinical researcher. She is vice chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as director of the Adult Survivorship Program and co-founder and director of the Program for Young Women with Breast Cancer. As a professor at Harvard Medical School, Dr. Partridge holds the Eric P. Winer, MD Chair in Breast Cancer Research at Dana-Farber. She leads clinical research and educational efforts nationally and internationally, and is particularly committed to improving outcomes for young women with breast cancer. Dr. Partridge serves on the Board of Directors of the American Society of Clinical Oncology (ASCO), co-chairs the National Cancer Institute (NCI) Alliance for Clinical Trials in Oncology Breast Committee, and serves on the NCI Breast Cancer Steering Committee. She is Chief Scientific Advisor for Susan G. Komen, and her research has been supported by the NCI, Breast Cancer Research Foundation (BCRF), Conquer Cancer, and Susan G. Komen. Dr. Partridge has received a Champions of Change award from the U.S. White House, the American Association for Clinical Research (AACR) Outstanding Investigator Award for Breast Cancer, and ASCO’s Ellen L. Stovall Award for Advancement of Cancer Survivorship Care.
Sarah E Pinder is Chair of Breast Pathology at King’s College London and Lead Breast Pathologist at Guy’s & St Thomas’ Hospitals.
She Chairs the National Coordinating Committee for Breast Pathology (NCCBP) for the Royal College of Pathologists & the UK NHS Breast Screening Programme. She is President of the Association of Breast Pathology.
She is pathologist for the low risk DCIS trial (LORIS), OPTIMA, MAMMO50, SMALL, NOSTRA and EndoNET trials, amongst others.
Her translational research interests are focused on in situ breast carcinoma, but include a wide range of collaborative work.
She has published over 350 articles in the peer-reviewed literature, and over 100 invited articles and chapters in textbooks.
Shelley Potter PhD FHEA FRCS
Shelley Potter is Professor of Surgical Oncology at Bristol Medical School and Consultant Oncoplastic Breast Surgeon at North Bristol NHS Trust.
Her research interests focus on improving outcomes for women with breast cancer through the development and delivery of high-quality patient-centred research. She is an experienced researcher who had led several national and international collaborative oncoplastic and reconstructive breast surgical projects including the iBRA and TEAM studies and is currently Chief Investigator for Brighter, ANTHEM and Pre-BRA. Recent work has focused on optimisation of breast cancer treatment.
Her leadership national roles include Royal College of Surgeons of England Surgical Specialty Lead for Breast Surgery, Chair of iBRA-NET and Secretary to the British Breast Group.
Dr Alistair Ring is a Consultant Medical Oncologist at The Royal Marsden. He undertook his pre-clinical training at the University of Cambridge and clinical training at the University of Oxford, qualifying in 1997. His oncology training was based at The Royal Marsden, St George’s and Guy’s Hospitals, London. He gained his MD research degree in 2005 from the Institute of Cancer Research (ICR) at the University of London.
In 2008 he was appointed as Senior Lecturer in Oncology at Brighton and Sussex Medical School and in 2014 he was appointed Consultant Medical Oncologist at The Royal Marsden.
He has a major interest in research and is UK lead for a number of research studies examining the roles of aspirin and modern targeted drugs in the management of breast cancer. He is Chair of the Committee for Clinical Research at The Royal Marsden and the ICR.
In 2018 Dr Ring was appointed Honorary Reader in Breast Cancer Clinical Trials, at the Institute of Cancer Research.
Laszlo Romics is a consultant oncoplastic breast and general surgeon at Greater Glasgow and Clyde Health Board and regional QA lead of NHS Scotland Breast Screening Programme. He is widely published, most recently on the oncological safety and clinical outcomes of oncoplastic breast conservation surgery, with altogether over 2,200 citations.
Dr Allison Rose MBBS, MMed, FRANZCR
Director, Northwestern BreastScreen
Head, The Royal Melbourne & The Women’s Hospital Breast Imaging Service
Associate, University of Melbourne Radiology Department
Dr Allison Rose was appointed at The Royal MelbourneHospital as one of the original
radiologists with the Victorian Pilot breast cancer screening program in 1989
and became Director ofNorthwestern BreastScreen in 1999. In 2009 she became Head of Breast Imaging for The
Royal Melbourne Hospital and Womens Hospital Breast Service. She established Breast MRI & MRI guided biopsy for the service and since 2015, CEM. She is a keen educator having launched Melbourne Breast MRI Intensive interactive workstation based Courses in 2011. These are now cloud based have been expanded to include CEM. Her research interests include de-escalation of breast cancer treatment, tailored screening for breast cancer, and breast cancer staging and surveillance.
Sukhwinder Sahota, UK
Sarah Savaridas
Sarah is a Senior Clinical Lecturer at the University of Dundee were she has recently been awarded an MD from the University of Dundee for her doctoral research into Contrast Enhanced Mammography. She is an honorary radiology consultant in NHS Tayside and the QA lead for the East of Scotland Breast Screening Service.
Her research interests include advanced breast imaging techniques; such as Contrast Mammography, abbreviated MRI and radiomics. She is also interested in addressing inequalities in access to breast screening and imaging services, and ensuring that all women can access appropriate information to support informed decision making.
Elinor Sawyer is Professor of Breast Cancer Molecular Genetics and Head of Cancer Care, Comprehensive Cancer Centre at King’s College London. She is also Honorary Consultant in Clinical Oncology at Guy’s Cancer Centre. She trained as a clinician scientist at the London Research Institute. Her PhD focused on the molecular genetics of phyllodes tumours. Her current research interests are genetic predisposition to breast cancer, particularly lobular breast cancer and DCIS, with a focus on identification of biomarkers that predict progression of LCIS and DCIS. She is a member of the Sloane Steering Committee (a national UK audit of screen detected DCIS) and leads on the molecular analyses of the UK DCIS samples in the CRUK Grand Challenge, PRECISION, and the application of these findings to clinical practice. She is on the Trials Management Group of three National UK radiotherapy studies (IMPORT–LOW, IMPORT–HIGH, Fast Forward) and is also involved in the translational studies associated with these trials.
Dr. Karla Sepulveda is a Professor of Radiology at Baylor College of Medicine and Medical Director of Breast Imaging at Baylor St. Luke’s Medical Center in Houston. TX. She holds the Pat Korell Endowed Professorship of Breast Imaging. Dr. Sepulveda completed her fellowship in Breast Imaging at MD Anderson Cancer Center. She is active in the American College of Radiology and Texas Radiological Society and uses this work to advocate for high value, multidisciplinary care for breast cancer patients. Her areas of professional interest include healthcare innovation, the role of radiology in precision oncology, and applications of artificial intelligence in breast imaging.
Dr. Nisha Sharma is a consultant breast radiologist and Director of the Breast Screening program Leeds/Wakefield. She is active in research involving new technologies, artificial intelligence and improving the patient pathway. She is a professional clinical advisor for breast screening and NHS England.
Professor Richard Simcock FRCR is a Consultant Clinical Oncologist at University Hospitals Sussex NHS Foundation Trust in Brighton, UK. Richard is also Chief Medical Officer at Macmillan Cancer Support, the UK’s largest cancer support charity, where recent projects have included development of psychological support systems for people affected by cancer across the UK, updated cancer Prehabilitation guidance and Frailty in Cancer guides alongside new initiatives for cancer related fatigue. Richard also has interests in cancer in pregnancy (and is Medical Advisor to ‘Mummy’s Star’) and cancer in older people.
He is on ‘X’ @BreastDocUK.
Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.
Dr. Mark Verrill is a Consultant Medical Oncologist, Breast Cancer
Newcastle upon Tyne Hospitals Foundation NHS Trust
Medical Oncology Clinical Lead, National Audits of Primary and Metastatic Breast Cancer, National Cancer Audit collaborating Centre
After studying medicine at Cambridge and University College London, Dr Verrill completed medical oncology training at the Royal Marsden Hospital and the Institute of Cancer Research.
He moved to Newcastle in 1999 as Cancer Research UK Senior Lecturer in Medical Oncology before taking up his current NHS post in 2007. His main interest is systemic therapies in breast cancer with a strong focus on clinical trials.
Dr. Frank A. Vicini has held multiple academic appointments and has been involved in numerous clinical studies involving breast and prostate cancer. He has designed, developed and completed numerous phase I/II and III NIH/NCI clinical trials to evaluate new and improved techniques to treat patients with Stage I and II breast cancer. Dr. Vicini has authored over 300 peer-reviewed articles and presented his research at national and international meetings. He is a visiting professor in both the United States and Europe, authored multiple chapters in textbooks and is on the editorial board of several oncology journals. In addition, he is listed as one of the few oncologists in “Best Oncology Doctors in America.” Dr. Vicini was recently named 21st Century Oncology’s National Principal Investigator.
Dr Raghavan Vidya is a Senior lecturer at Birmingham University and Consultant Oncoplastic breast surgeon at the Royal Wolverhampton NHS Trust. She graduated from University of Madras, India followed by Postgraduate training in General Surgery. She completed her MD (Research) on aromatase inhibitors from University of Edinburgh. She has introduced and mentored new innovations including muscle-sparing implant-based breast reconstruction.
She serves as a Trustee of the Association of Breast surgery and actively contributes to its working. Dedicated to teaching and training, she contributes actively as a Higher Surgical Trainer, delivers lectures, and runs workshops as invited faculty for national and international meetings. Through her role as Royal College, International Surgical Training Programme Lead for Breast Surgery, she is committed to advancing breast training. She has a strong focus towards clinical research exemplified by over 150 publications. She has published two books on breast reconstruction and an ebook on Global Breast Training in collaboration with RCS and ABS. She promotes clinical application of Genomics in NHS as Associate Director of Genomics in West Midlands. She is actively involved in clinical trials and have a special interest in new technology and advances in breast surgery.
Lynda Wyld, MB,ChB, PhD, FRCS, FEBS
Lynda Wyld underwent surgical training in the UK, spending time in Sheffield, Nottingham and Manchester. She did her PhD at the University of Sheffield. She was appointed to an academic post at the University of Sheffield in 2002 and is now Professor of Surgical Oncology. Her clinical interest is the management of breast cancer and she practices as a Consultant Oncoplastic Breast Surgeon at Doncaster Teaching Hospitals in the UK. Her main research interest is in age related inequalities in cancer surgery where she has led projects to improve outcomes and develop decision aids for older women with breast cancer. Her other career focus has been to develop training in cancer surgery and in particular to see the development of breast surgery. She has been a member of BASO since 1997, winning the Raven Prize in 1998, joining the board of Trustees in 2010, becoming secretary in 2012 and President between 2015 and 2017. She is also past chair of the education and training committee of ESSO (2012-2018) and is the current secretary and president elect of the UEMS European Breast Examination Board. She is a trustee of the ABS.